BioMed Research International / 2019 / Article / Tab 3

Research Article

Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women

Table 3

Univariate analysis of various factors for NAFLD assessed by abdominal US in women with and without NAFLD.

FactorsNo NAFLD
n(%)
NAFLD
n(%)
Odd ratios95 %CIP-value

WC
 ≤ 8021(72.41)8(27.59)1-0.002
 > 8011(32.35)23(67.65)5.491.66- 18.11
BMI
 < 2520(68.97)9(31.03)1-0.008
 ≥ 2512(35.29)22(64.71)4.071.32- 12.60
FBS
 < 10031(54.39)26(45.61)1-0.104
 ≥ 1001(16.67)5(83.33)5.960.61- 58.51
2 hrs Glucose
 < 14029(52.73)26(47.27)1-0.474
 ≥ 1403(37.50)5(62.50)1.860.40-8.73
Biochemical HA
 No25(59.52)17(40.48)1-0.064
 Yes7(33.33)14(66.67)2.940.94-9.20
Clinical HA
 No19(59.38)13(40.63)1-0.166
 Yes13(41.94)18(58.06)2.020.72-5.65
Total HA
 No16(64.00)9(36.00)1-0.123
 Yes16(42.11)22(57.89)2.440.83-7.15
Insulin Resistance(IR)
 No21(63.64)12(36.36)1-0.045
 Yes11(36.67)19(63.33)3.021.03-8.85
Abnormal Glucose
 No28(60.87)18(39.13)1-0.015
 IGT4(28.57)10(71.43)3.890.99-15.23
 DM0(0.00)3(100.00)4.550.48-43.07
TG
 < 15031(55.36)25(44.64)1-0.053
 ≥ 1501(14.29)6(85.71)7.440.76-72.47
HDL
 < 5010(31.25)22(68.75)5.381.65-17.560.002
 ≥ 5022(70.97)9(29.03)1-
LDL
 ≤ 13019(63.33)11(36.67)1-0.058
 > 13013(39.39)20(60.61)2.660.92-7.66
Metabolic Syndrome
 No31(57.41)23(42.59)1-0.013
 Yes1(11.11)8(88.89)10.781.09-106.31
PCOS0.479
 No12(57.14)9(42.86)1-
 Yes20(47.62)22(52.38)1.470.50-4.27

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.